It is to be hoped, in the light of the above issues, that the ICS in formulating guidelines emphasises the need for greater publicity and genuinely informed consent as a pre-condition for supporting the initiative of NHBOD. This would not only offer protection to all parties, but if organ donation at optimal viability was an explicit goal, patient care could reasonably accommodate those interventions directed to this end that Drs Bonner and Manara define as 'inappropriate and unacceptable', thereby minimising hazard to the potential recipient. Without this detailed public engagement and platform of valid consent, the reputation of intensive care will be vulnerable to destructive concerns over covert conflicts-of interests. The 'challenge' lies not in dismissing those concerns but in accepting their legitimacy and seeking a longer-term but ultimately more sustainable solution. The originators of the statement were the Executive Officers of the Society. The statement was made in response to further questions from the Society's members following Prof David Bennett's comments on radio. They need to be seen in that context. The contribution to the Society made by Lilly (and all our other sponsors for that matter) was acknowledged at the top of Page 102 of that volume of JICS. The Society has a generic statement of interest where such support is acknowledged and this accompanied our NICE submission.
I hope this reassures you that the Society does indeed take its independence seriously and when appropriate makes the correct declaration.
Best wishes Saxon

Dear Editor
Thanks for Saxon's reply. I don't think the vote of thanks to Industry Members posted under 'Miscellaneous' on page 102 counts as a declaration of interest on behalf of what you now tell me was a statement by the Executive Officers. I would expect to see their individual names and individual Declarations of Interest attached to such a Statement.
I personally do not doubt the integrity of the Officers of the Society, but I am concerned about the impression outsiders might have, and so our standing in the professional community. I cannot imagine the RCA, the RCP, the AAGBI, or the BMA making a Statement like this, endorsing a pharmaceutical product by its trade name and criticising DoH appraisal procedures. Why did we need to do it? David Bennett has made the news sound bite, and is a big boy who does not need our endorsement for his credibility.
The Central Southern CCN has taken a slightly different position from the Execs of ICS. I think this is an appropriate role for a Network.
It is probably a good thing this Statement got buried in the Correspondence section, attributed to Rachel Mann according to the Contents listing, and was not alluded to in 'The Editor writes' or the 'President's Report'. Most people won't notice it. Tom
